This week’s Endocrinology update highlights regulatory actions, diabetes technology progress, GLP-1 access shifts, pipeline data, and care-model developments.
In Today’s Newsletter
Dive deeper
🤰 Tandem Control-IQ cleared for pregnancy in type 1 diabetes [1] [US • 27 Apr 2026]
https://www.drugdeliverybusiness.com/tandem-fda-clearance-aid-pregnancy-t1d/
Context: Tandem Diabetes Care’s Control-IQ+ powers the t:slim X2 and Mobi automated insulin delivery systems.
Key point: FDA cleared Control-IQ technology for pregnancy complicated by type 1 diabetes mellitus.
Implication: May influence prescriber choice and payer reviews pending full data.
🩸 Glucotrack implantable CBGM study published [2] [US • 30 Apr 2026]
https://www.chartmill.com/news/GCTK/gnwcq-2026-4-30-glucotrack-announces-publication-of-peer-reviewed-study-in-the-journal-of-diabetes-research-demonstrating-long-term-accuracy-and-stability-of-continuous-blood-glucose-monitoring-technology
Context: The Journal of Diabetes Research paper evaluated 34 implanted devices in 17 adult sheep for up to 240 days.
Key point: Glucotrack reported 6.8% weighted average MARD, consistent sensing, and no device-related adverse safety events in the ovine model.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
📊 Ascletis obesity programs headed to ADA 2026 [3] [US • 30 Apr 2026]
https://www.prnewswire.com/apac/news-releases/ascletis-to-present-data-on-multiple-programs-at-the-american-diabetes-associations-2026-scientific-sessions-302757320.html
Context: Ascletis Pharma will present posters at the ADA 2026 Scientific Sessions in New Orleans, 05–08 Jun 2026.
Key point: Presentations include ASC39, ASC30, and ASC37 programs across oral amylin, oral GLP-1, and triple agonist approaches.
Implication: Signals pipeline investment and modality expansion.
💊 Novo Nordisk Ozempic pill launching in the US [4] [US • 01 May 2026]
https://www.prnewswire.com/news-releases/novo-nordisks-ozempic-pill-the-only-fda-approved-oral-peptide-glp-1-medication-for-adults-with-type-2-diabetes-soon-to-be-available-in-the-us-302760106.html
Context: Novo Nordisk said Ozempic (semaglutide) tablets 1.5 mg, 4 mg, and 9 mg will be available starting 04 May 2026.
Key point: The company positioned Ozempic pill as an oral GLP-1 option for adults with type 2 diabetes, including MACE risk-reduction labeling in high-risk adults.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.
👨👩👧 Breakthrough T1D Canada caregiver guide launched [5] [Canada • 01 May 2026]
https://breakthrought1d.ca/new-caregiver-guide-launched-for-parents-and-caregivers-of-children-and-youth-with-type-1-diabetes/
Context: Breakthrough T1D Canada developed the guide with input from Canadian mental health providers and people with lived experience.
Key point: The caregiver guide addresses diagnosis, school transitions, child independence, siblings, stress, coping, and when to seek support.
Implication: May expand screening, initiation, and follow-up at scale.
🏥 UMass, Shields pharmacy model reports diabetes gains [6] [US • 29 Apr 2026]
https://www.hmpgloballearningnetwork.com/site/frmc/conference-coverage/health-system-specialty-pharmacy-model-shows-promise-diabetes
Context: UMass Memorial Health and Shields Health Solutions described a specialty pharmacy care-coach model at Asembia 2026.
Key point: The program combined medication support, care coordination, social-needs screening, behavioral health referral, and coaching for high-risk diabetes patients.
Implication: Could inform practice and payer discussions; interpretation depends on study design and confounding control.
🇨🇦 Apotex wins Health Canada approval for generic semaglutide injection [7] [Canada • 01 May 2026]
https://www.prnewswire.com/news-releases/apotex-becomes-the-first-canadianbased-pharmaceutical-company-to-receive-health-canada-approval-for-a-generic-equivalent-of-ozempic-302760415.html
Context: Apo-Semaglutide Injection is a generic equivalent of Ozempic (semaglutide injection) for adults with type 2 diabetes in Canada.
Key point: Health Canada approved two prefilled pen formats, including 0.25 mg or 0.5 mg dosing and 1 mg dosing.
Implication: Introduces competition that may affect pricing and formulary access.
🌍 Cirius gestational diabetes initiative receives Gates planning grant [8] [Global • 28 Apr 2026]
https://www.prnewswire.com/news-releases/cirius-therapeutics-announces-gestational-diabetes-initiative-302756216.html
Context: Cirius Therapeutics is developing CIR-0602K, an oral MPC inhibitor, for diseases linked to mitochondrial dysfunction and insulin resistance.
Key point: A Gates Foundation planning grant will support work on CIR-0602K as a potential postpartum therapy for women with prior gestational diabetes.
Implication: Signals pipeline investment and modality expansion.
Why It Matters
- Diabetes technology is moving into narrower high-need populations, including pregnancy with type 1 diabetes.
- GLP-1 access is expanding through new oral branding in the US and generic semaglutide injection approval in Canada.
- Metabolic-disease pipelines continue to broaden beyond GLP-1, including amylin, triple agonists, and MPC inhibition.
- Care delivery models are becoming more integrated, with pharmacy, behavioral health, social support, and coaching linked in one workflow.
- Caregiver mental health is being treated as part of diabetes management, especially in pediatric type 1 diabetes.
🎯 Catch up on the Top Endocrinology news from the past two weeks, curated by the LucidQuest team.
📚 View the full Endocrinology archive on our research hub page
🚀 Accelerate your success. Contact us now
📂 Explore our case studies. See examples of our work.
💡 Read our insights. Learn from our latest reports and analysis
🧰 See our full range of services. Discover how we can help you.
FAQ
What did FDA clear for Tandem Diabetes Care?
FDA cleared Tandem’s Control-IQ automated insulin delivery technology for use in pregnancy complicated by type 1 diabetes mellitus. The source says Control-IQ+ powers Tandem’s t:slim X2 and Mobi systems. [1]
What did Glucotrack publish about its implantable CBGM system?
Glucotrack announced a peer-reviewed Journal of Diabetes Research study in an ovine model. The study reported long-term accuracy and stability for its fully implantable continuous blood glucose monitoring system. [2]
Which Ascletis programs will appear at ADA 2026?
Ascletis listed poster presentations for ASC39, ASC30, and ASC37. These include oral amylin, oral GLP-1, and GLP-1R/GIPR/GCGR triple agonist approaches. [3]
What is changing for Novo Nordisk’s Ozempic in the US?
Novo Nordisk said Ozempic tablets will become available in the US for adults with type 2 diabetes. The company described this as an updated formulation and branding for oral semaglutide. [4]
What did Health Canada approve for Apotex?
Health Canada approved Apo-Semaglutide Injection, a generic equivalent of Ozempic injection. Apotex said the product is indicated in Canada for once-weekly treatment of adults with type 2 diabetes to improve glycemic control with diet and exercise. [7]
What is Cirius Therapeutics studying with Gates Foundation support?
Cirius received a planning grant to support development work for CIR-0602K as a potential postpartum therapy for women with a history of gestational diabetes. The first phase focuses on planning, regulatory alignment, and potential breast-milk exposure assessment. [8]
Entities / Keywords
Tandem Diabetes Care, Control-IQ, Control-IQ+, t:slim X2, Mobi, SteadiSet, automated insulin delivery, AID, type 1 diabetes, pregnancy
Glucotrack, continuous blood glucose monitor, CBGM, implantable glucose monitor, MARD, ovine model
Ascletis Pharma, ASC39, ASC30, ASC37, oral amylin receptor agonist, oral GLP-1, triple agonist, ADA 2026
Novo Nordisk, Ozempic pill, Ozempic tablets, semaglutide tablets, Rybelsus, oral peptide GLP-1, type 2 diabetes, MACE
Breakthrough T1D Canada, caregiver guide, type 1 diabetes, pediatric T1D, caregiver mental health
UMass Memorial Health, Shields Health Solutions, health system specialty pharmacy, care coach, Asembia 2026, A1C
Apotex, Apo-Semaglutide Injection, generic Ozempic, semaglutide injection, Health Canada, Orbicular Pharmaceutical Technologies
Cirius Therapeutics, CIR-0602K, Gates Foundation, gestational diabetes mellitus, GDM, postpartum therapy, MPC inhibitor, Certara, LMIC
References
- https://www.drugdeliverybusiness.com/tandem-fda-clearance-aid-pregnancy-t1d/
- https://www.chartmill.com/news/GCTK/gnwcq-2026-4-30-glucotrack-announces-publication-of-peer-reviewed-study-in-the-journal-of-diabetes-research-demonstrating-long-term-accuracy-and-stability-of-continuous-blood-glucose-monitoring-technology
- https://www.prnewswire.com/apac/news-releases/ascletis-to-present-data-on-multiple-programs-at-the-american-diabetes-associations-2026-scientific-sessions-302757320.html
- https://www.prnewswire.com/news-releases/novo-nordisks-ozempic-pill-the-only-fda-approved-oral-peptide-glp-1-medication-for-adults-with-type-2-diabetes-soon-to-be-available-in-the-us-302760106.html
- https://breakthrought1d.ca/new-caregiver-guide-launched-for-parents-and-caregivers-of-children-and-youth-with-type-1-diabetes/
- https://www.hmpgloballearningnetwork.com/site/frmc/conference-coverage/health-system-specialty-pharmacy-model-shows-promise-diabetes
- https://www.prnewswire.com/news-releases/apotex-becomes-the-first-canadianbased-pharmaceutical-company-to-receive-health-canada-approval-for-a-generic-equivalent-of-ozempic-302760415.html
- https://www.prnewswire.com/news-releases/cirius-therapeutics-announces-gestational-diabetes-initiative-302756216.html